The US Food and Drug Administration (FDA) has approved Neffy, a nasal spray for treating severe allergic reactions in ...

Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.

Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments ...

Q4 2024 Earnings Call Transcript March 20, 2025 ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, ...

Good day, and welcome to ARS Pharmaceuticals fourth quarter and full year 2024 financial results conference call. (Operator Instructions) As a reminder, this call is being recorded. I would now like ...

This past week, my Motion 518: Expanding Availability of Epinephrine Auto-Injectors was successfully passed in Alberta’s ...

A retired firefighter, Sen. Kelly Seyarto has advocated to be more involved in disaster management work. A new committee ...

ARS Pharmaceuticals Inc (SPRY) reports robust revenue growth and strategic advancements in global commercialization, despite challenges in market adoption.

Earlier this year, the US Supreme Court declined to hear legal action against Viatris, which claimed that it was illegally monopolising the epinephrine auto-injector market through exclusive deals ...

Q4 2024 Management View Richard Lowenthal, Co-Founder and CEO, highlighted the successful launch of neffy 2mg in the U.S. and the FDA approval for neffy 1mg for pediatric use, targeting children ...